A Personalized Reality
Next generation sequencing holds much promise for personalized cancer diagnosis, treatment and management, but how is this being realized and what does the future hold?
Matthew Smith , George Burghel - |
At a Glance
- Molecular tumor profiling of clinically actionable mutations using NGS guides the delivery of anti-cancer therapies
- Fast, efficient and cost-effective, targeted NGS is becoming increasingly embedded into the clinical laboratory
- Certain factors are vital for accurate clinical data, such as quality control, FFPE sample compatibility and an optimized target capture assay
- Targeted panels are emerging and evolving in response to the latest genetic discoveries
Clinically actionable mutations lying within certain driver genes are central to tumor development, and hold much utility for cancer medicine. While these mutations carry diagnostic, prognostic or predictive implications, a subset are also deemed ‘druggable’ – able of identifying cancers that can be treated with targeted therapies acting against the subsequent protein product or disturbed pathway.
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.